XML 43 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (15,356) $ (12,057)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 6 8
Stock-based compensation expense 2,527 3,271
Loss from equity method investment in Galectin Sciences LLC   390
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 350 108
Accounts payable and accrued expenses (Notes 2 and 8) 91 (1,033)
Net cash used in operating activities (12,382) (9,313)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Equity method investment in Galectin Sciences LLC   (400)
Net cash used in investing activities   (400)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from issuance of common stock and warrants 4,573 28,238
Proceeds from exercise of common stock warrants and options   2,187
Net cash provided by financing activities 4,573 30,425
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (7,809) 20,712
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 29,128 10,489
CASH AND CASH EQUIVALENTS, END OF PERIOD 21,319 31,201
NONCASH FINANCING ACTIVITIES:    
Payment of preferred stock dividends in common stock $ 629 $ 763